Apolipoprotein AI (Apo AI), constituting 75% of HDL-associated apolipoproteins, is a critical for reverse cholesterol transport (RCT), mediating cholesterol efflux from peripheral tissues to the liver. As the primary structural component of HDL, Apo AI stabilizes discoidal HDL particles, activates lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol, and facilitates HDL maturatioN. Its anti-inflammatory properties include blocking T-cell–monocyte interactions, reducing TNF-α and IL-1β production, and neutralizing oxidized LDL. Normal plasma levels range from 90–130 mg/100 mL, with concentrations inversely correlating with coronary heart disease (CHD) risk.
Deficiencies in Apo AI underlie Tangier disease, characterized by near-absent HDL, cholesterol-laden macrophages, and premature atherosclerosis. Mutations like APOA1 p.Leu202Arg cause systemic amyloidosis, leading to cardiac and renal dysfunction. Reduced Apo AI levels also associate with insulin resistance, impaired β-cell function, and diabetes progression. Conversely, Apo AI overexpression enhances macrophage-specific RCT, attenuating atherosclerosis.
Common uses include IVD standards, calibrators, and controls, lipid metabolism studies, biotherapeutic studies, cell based assays.
Not a hazardous substance or mixture.
12 - Non Combustible Liquids